TY - JOUR
T1 - Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer
AU - Tresoldi, Alberto S.
AU - Sburlati, Laura F.
AU - Rodari, Marcello
AU - Schinkelshoek, Mink
AU - Perrino, Michela
AU - De Leo, Simone
AU - Montefusco, Laura
AU - Colombo, Paolo
AU - Arosio, Maura
AU - Lania, Andrea Gerardo Antonio
AU - Fugazzola, Laura
AU - Chiti, Arturo
PY - 2014
Y1 - 2014
N2 - Purpose: The aim of this study was to evaluate the efficacy of post-operative radioiodine ablation with 1,850 MBq after recombinant human thyrotropin (rhTSH) administration in patients with differentiated thyroid carcinoma (DTC). We also aimed to assess the prognostic role of several patient features on the outcome of ablation. Methods: We retrospectively analyzed data from a total of 125 patients with DTC who underwent post-operative radioiodine ablation with 1,850 MBq of 131I after preparation with rhTSH. One injection of 0.9 mg rhTSH was administered on each of two consecutive days; 131I therapy was delivered 24 h after the last injection, followed by a post-therapy whole-body scan. Successful ablation was assessed 6-12 months later and defined as an rhTSH-stimulated serum thyroglobulin (Tg) level ≤1.0 ng/ml and a normal neck ultrasound. Results: Patients were stratified according to the American Thyroid Association (ATA) Management Guidelines for Differentiated Thyroid Cancer. Successful ablation was achieved in 82.4 % of patients, with an ablation rate of 95.1 % in low-risk patients and 76.2 % in intermediate-risk patients. Analyzing the correlation between ablation outcome and patient characteristics, we found a statistically significant association between failure to ablate and class of risk based on ATA guidelines (p = 0.025) and a stimulated Tg value at ablation of above 5 ng/ml (p <0.001). Conclusion: The use of 1,850 MBq post-operative radioiodine thyroid remnant ablation in association with rhTSH is effective for low- and intermediate-risk patients. Moreover, in our study, we found a statistical correlation between failure to ablate and class of risk based on ATA guidelines for DTC and a stimulated Tg value at ablation.
AB - Purpose: The aim of this study was to evaluate the efficacy of post-operative radioiodine ablation with 1,850 MBq after recombinant human thyrotropin (rhTSH) administration in patients with differentiated thyroid carcinoma (DTC). We also aimed to assess the prognostic role of several patient features on the outcome of ablation. Methods: We retrospectively analyzed data from a total of 125 patients with DTC who underwent post-operative radioiodine ablation with 1,850 MBq of 131I after preparation with rhTSH. One injection of 0.9 mg rhTSH was administered on each of two consecutive days; 131I therapy was delivered 24 h after the last injection, followed by a post-therapy whole-body scan. Successful ablation was assessed 6-12 months later and defined as an rhTSH-stimulated serum thyroglobulin (Tg) level ≤1.0 ng/ml and a normal neck ultrasound. Results: Patients were stratified according to the American Thyroid Association (ATA) Management Guidelines for Differentiated Thyroid Cancer. Successful ablation was achieved in 82.4 % of patients, with an ablation rate of 95.1 % in low-risk patients and 76.2 % in intermediate-risk patients. Analyzing the correlation between ablation outcome and patient characteristics, we found a statistically significant association between failure to ablate and class of risk based on ATA guidelines (p = 0.025) and a stimulated Tg value at ablation of above 5 ng/ml (p <0.001). Conclusion: The use of 1,850 MBq post-operative radioiodine thyroid remnant ablation in association with rhTSH is effective for low- and intermediate-risk patients. Moreover, in our study, we found a statistical correlation between failure to ablate and class of risk based on ATA guidelines for DTC and a stimulated Tg value at ablation.
KW - Cancer
KW - Radioiodine
KW - RhTSH
KW - Thyroid
UR - http://www.scopus.com/inward/record.url?scp=84907307294&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907307294&partnerID=8YFLogxK
U2 - 10.1007/s40618-014-0088-3
DO - 10.1007/s40618-014-0088-3
M3 - Article
C2 - 24844565
AN - SCOPUS:84907307294
SN - 0391-4097
VL - 37
SP - 709
EP - 714
JO - Journal of Endocrinological Investigation
JF - Journal of Endocrinological Investigation
IS - 8
ER -